Tillotts Pharma in Germany Dedicated to Gastrointestinal Health

PR67516

BERLIN, Feb. 23, 2017 /PRNewswire=KYODO JBN/

     Tillotts Pharma is strengthening its presence in the German market: the

Berlin office was opened in January 2017 under the management of Magdalena

Kritikos. The portfolio includes Entocort(R) for the treatment of Crohn's

disease, Asacol(R) for the treatment of ulcerative colitis, and VistaPrep(R)

for bowel preparation before endoscopy. With further innovative solutions, the

Swiss specialty pharmaceutical company focused on the treatment of

gastrointestinal (GI) diseases will expand its global footprint with its

growing presence in Germany and will continue to work to improve the quality of

life for patients.   

     Tillotts Pharma GmbH began its activities in the heart of the capital in

January this year. Magdalena Kritikos, with many years' experience in

pharmaceutical management and now the general manager of Tillotts Pharma in

Germany, says: "We will be building up to a 20-strong team over the next few

months. Half the members are already on board. We are looking forward to

working with our customers and providing them with active support in the field

of gastrointestinal health."

     (Photo: http://mma.prnewswire.com/media/471358/Magdalena_Kritikos.jpg )

     Tillotts Pharma has been dedicated to the health of the digestive system

for more than 30 years offering its products in more than 65 countries. "Our

key strengths are prescription medicines for the treatment of chronic

inflammatory bowel diseases," explains Magdalena Kritikos. "And we are

continuing to develop our portfolio of innovative treatment solutions to

improve the quality of life for patients. Our pipeline is well filled, so that

we are well prepared for the future." Today, the Tillotts Pharma GmbH portfolio

includes Entocort(R), a treatment for Crohn's disease, Asacol(R), a treatment

for ulcerative colitis, and VistaPrep(R) for bowel cleansing prior to

colonoscopy.

     Studies have shown that the number of patients with chronic inflammatory

bowel disease is increasing[1]. Between 320,000[2] and 470,000[3] people are

affected in Germany alone, with more than five million sufferers worldwide[4].

"Young people between the ages of 16 and 35 are particularly affected by these

complex diseases, which are often associated with diarrhoea, cramp-like

abdominal pain and considerable negative impact on both professional and

private life[5]," adds Magdalena Kritikos. "We want to actively contribute by

broadening the therapeutic options so that patients and their families can lead

as normal lives as possible."

     The development, production, and worldwide marketing of medicines for

treating the GI tract is coordinated by Tillotts Pharma AG in Rheinfelden,

Switzerland. The company, which belongs to the Japanese Zeria group, is

actively engaged in dialogue with medical professionals and sponsors continuing

medical education for doctors, e.g. the educational symposium during the

European Crohn's and Colitis Organisation (ECCO) Congress which took place on

17 February 2017 in Barcelona.

     Tillotts Pharma GmbH, with registered offices in Berlin and Rheinfelden,

is an affiliate of the Swiss Tillotts Pharma AG.

     Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing

specialty pharmaceutical company with over 250 employees in Switzerland and

abroad. Tillotts is dedicated to the development, in/out licensing and

commercialisation of innovative pharmaceutical products for the digestive

system. Tillotts successfully markets its own products Asacol(TM) and Entocort(TM),

as well as in-licensed products, in over 65 countries through its affiliates

within Europe and a network of gastroenterology-focused partners throughout the

world.

     All trademarks used or mentioned here are protected by law. The rights to

Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG

in various countries except for the following: Belgium, Canada, Italy,

Luxembourg, the Netherlands, Switzerland, United Kingdom and USA. The rights to

Entocort, including the rights to the trademark, are owned by Tillotts Pharma

AG in various countries (transfer of market authorisations to Tillotts Pharma

in process) except for the USA. The rights to Vistaprep, including the rights

to the trademark, are owned by Tillotts Pharma AG in various countries.

     Product information in this release is limited, with the aim of providing

a summary for general information purposes for a wide audience regarding the

activities of Tillotts, and could contain product details or information not

accessible or valid in your country. Tillotts disclaims responsibility for

access of information which may not comply with any regulation or standard in

any particular country. More information may be available from local regulatory

authorities, but not all products are available in each country. Please consult

a healthcare professional for further information.

     (C) Copyright Tillotts Pharma AG. All rights reserved.

--------------------------------------------------

     1. Molodecky NA, et al.: Increasing incidence and prevalence of the

inflammatory bowel diseases with time, based on systematic review.

Gastroenterology

[http://www.gastrojournal.org/article/S0016-5085(11)01378-3/abstract ] 2012;

142: 46-54; Gastroenterology

[http://www.gastrojournal.org/article/S0016-5085(11)01378-3/abstract  ]

     2. Bokemeyer B: CED-Behandlung in Deutschland. Der Gastroenterologe

[http://link.springer.com/article/10.1007%2Fs11377-007-0113-6 ] 2007, 2:

447-455; Der Gastroenterologe

[http://link.springer.com/article/10.1007%2Fs11377-007-0113-6 ]

     3. Stallmach A et al.: Die chronisch-entzundlichen Darmerkrankungen Morbus

Cohn and Colitis ulcerosa. Gesundheitswesen aktuell 2012, 286-309; Barmer GEK

[https://www.yumpu.com/de/document/view/15919925/die-chronisch-entzundlichen-dar

merkrankungen-barmer-gek ]

     4. Kaplan G: The global burden of IBD: from 2015 to 2025. Nature Reviews

Gastroenterology & Hepatology 2015, 12, 720-727, nature

[http://www.nature.com/nrgastro/journal/v12/n12/abs/nrgastro.2015.150.html  ]

     5. http://www.kompetenznetz-ced.de/darmerkrankungen.html

     Contact person, Tillotts Pharma GmbH:

     Magdalena Kritikos

     General Manager

     Phone: +49-30-88706-7774

     Email: mkritikos@tillotts.com

     http://www.tillotts.de

SOURCE: Tillotts Pharma AG